What You Should Know About Global Health Financing Transitions: Five Key Takeaways

Christina Shaw
Christina Shaw

Knowledge Management & Communications Officer

Results for Development

Projected Health Financing Transitions: Timeline and Magnitude, a new working paper that was recently released, maps out an indicative timeline of transition through 2040 across five global health financing mechanisms, including Gavi, the Vaccine Alliance. Research findings from the paper show that:

  • By 2040, Gavi will see major transformations of its funding portfolios
  • Countries in the most fiscal jeopardy from anticipated transition are not those transitioning based on GDP per capita or disease burden, but instead those that are likely to be impacted by the near-term wind-down of GPEI and reallocations of PEPFAR financing

Based on this working paper, the author put together the top five key takeaways that countries preparing for transition should be aware of.

You May Also Like

COVAX Application Materials for AMC Eligible Economies Now Available

The COVAX Facility released the application and guidance documents (“application package”) for eligible economies to (i) confirm participation in the COVAX Facility and (ii) request support as part of COVAX. This comprises COVID-19 vaccines, as well as Cold Chain Equipment and Technical Assistance needed to prepare for the delivery of COVID-19 vaccines.  All 92 AMC Eligible … Read More

COVID-19: Gavi steps up response to pandemic

Gavi, the Vaccine Alliance, will provide US$ 29 million in urgent initial funding to 13 lower-income countries to support their response to COVID-19, helping them to protect health care workers with personal protective equipment (PPE), perform vital surveillance and training, and fund diagnostic tests. There are further requests or interest from 21 countries, meaning more … Read More

Center for Global Development – Global Immunization and Gavi: Five Priorities for the Next Five Years

Below is an excerpt from the Center for Global Development’s overview note.  Child vaccination remains among the most cost-effective uses of public and aid monies.[1] In a highly contested funding environment where priorities must be set for the allocation of scarce concessional resources, investment in expanding the availability and coverage of cost-effective vaccination must come … Read More